12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Q-Pan H5N1 adjuvanted regulatory update

FDA's Vaccines and Related Biological Products Advisory Committee voted 14-0 that safety and immunogenicity data support accelerated approval of Q-Pan H5N1 adjuvanted vaccine from GlaxoSmithKline to prevent disease in adults who are at an increased risk of exposure to the influenza A virus subtype H5N1. The panel was divided on the non-voting topic of the options by which GSK can confirm Q-Pan H5N1's clinical benefit...

Read the full 302 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >